Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for ...

Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its ...

Recent hiccups related to manufacturing plant issues and tariff uncertainties have led to volatility in earnings and, ...

Aurobindo Pharma Limited announced mixed performance during the quarter ended June 2025. The business reported a consolidated ...

Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter ...

Aurobindo Pharma reports a 10.2% YoY drop in Q1 FY26 PAT, citing API sales and US market revenue decline. The company's ...

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in ...

Aurobindo Pharma's consolidated net profit fell by 10.2% to ₹824 crore in Q1, despite a 4% increase in revenue driven by European and growth market sales.

Shree Cements, Aurobindo Pharma, DLF, Siemens Energy, Bosch, and Marico among 192 companies to release earnings report today.

Following US President Trump's tariff announcement, Indian pharmaceutical and textile companies experienced significant stock ...

Aurobindo Pharma reported a 10.2% YoY decline in Q1 net profit to ₹824.2 crore, missing CNBC-TV18 estimates. Revenue rose 4%, ...